Trial reportBlood purification2025
Regional Practice Variation in the Management of Renal Replacement Therapy Modalities in the STARRT-AKI Trial.
Trial report in Blood purification, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management.Critical care (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: The assess whether, in high-income countries, in the STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial, the management of the chosen initial renal replacement therapy modality varied by region and whether such variation was associated with different outcomes.
methodsPost hoc analysis of the STARRT-AKI trial, including 142 ICUs in 13 countries. We evaluated 1,395 patients with severe AKI from North America, Europe, and Australia-New Zealand (ANZ) who received continuous renal replacement therapy (CRRT) as a first modality and 684 patients from North America and Europe who received intermittent hemodialysis (IHD) as a first modality.
resultsAmong CRRT-first patients, femoral vascular access (p < 0.001) and citrate anticoagulation were more common in Europe and ANZ (p < 0.001) before and after adjustment for baseline characteristics. Treatment in ANZ was independently associated with a more negative fluid balance (p = 0.029), less frequent transition to IHD (p = 0.040), and lower CRRT dose-intensity (p = 0.012). Among IHD-first patients, compared to Europe, treatment in North America was independently associated with less use of femoral access, and greater net ultrafiltration rate.
conclusionAt STARRT-AKI trial centers, there was significant region-dependent practice variation in the management of CRRT-first and IHD-first patients. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.